Avastin for Diabetic Retinopathy with Macular Edema and Cardiovascular Comorbidities

Primary Indication for Anti-VEGF Therapy

• The American Diabetes Association guidelines state that anti-VEGF therapy is indicated for diabetic macular edema 1
• For early proliferative diabetic retinopathy, anti-VEGF therapy is non-inferior to traditional panretinal laser photocoagulation for reducing vision loss risk 2
• Bevacizumab has demonstrated efficacy in regressing retinal neovascularization in PDR 2
• This patient meets criteria with center-involved macular edema and early PDR, making treatment medically necessary 3, 4

Appropriate Treatment Protocol

• Begin with at least 4 monthly injections of bevacizumab 1.25 mg 3, 4, 2
• Continue monthly injections until vision and edema are no longer improving or vision reaches 20/20 or better 3, 4
• PDR patients typically require near-monthly injections during the first year 2
• After initial loading, reassess at each monthly visit for improvement (defined as ≥5 letters visual acuity gain or ≥10% reduction in OCT central subfield thickness) 3, 4
• If no improvement occurs at consecutive visits after adequate loading, consider extending intervals to 6-8 weeks 2
• If edema resolves or vision reaches 20/20 with OCT central subfield <250 μm, treatment may be withheld with close monitoring 3, 4
• Resume monthly intervals if edema recurs or worsens 3, 4

Adjunctive Laser Therapy

• Focal/grid laser should be added if edema persists and is no longer improving after anti-VEGF injections 3, 4, 5
• Laser can be given either promptly (within 3-10 days) or deferred (at least 24 weeks) based on clinical judgment 3, 4

Critical Cardiovascular Safety Considerations

• Assess blood pressure at each visit, as VEGF inhibition can affect vascular homeostasis 1
• Coordinate care with cardiology if cardiovascular status changes 1
• Optimize glycemic control (HbA1c targets) and blood pressure control to reduce retinopathy progression risk 1

Common Pitfalls to Avoid

• Do not continue indefinite monthly injections without assessing for improvement 3, 4
• Do not stop treatment prematurely before adequate loading (minimum 4 injections) 2
• Do not ignore the need for adjunctive laser when anti-VEGF alone is insufficient 3, 4

Documentation for Medical Necessity

• Certification should specify diabetic macular edema with center involvement and early proliferative diabetic retinopathy as indications, with treatment protocol based on monthly response assessment rather than fixed intervals 1, 2